Podcasts about Ascent

In this episode, hear Allison Butts, PharmD, BCOP and Danielle Roman, PharmD, BCOP, share their insights on the best practices for incorporating antibody–drug conjugates (ADCs) into clinical practice including:An overview of ADC structure and mechanism of actionA topline review of data supporting the current FDA-approved indications for ADCs targeting HER2 and TROP-2 across multiple tumor typesAn in-depth look at common and serious adverse events with each approved ADC along with an overview of management strategiesEditor's note: On June 23, 2025, the FDA granted accelerated approval for a new indication for datopotamab deruxtecan, one of the antibody drug conjugates discussed in this podcast. Datopotamab deruxtecan is now also approved for adults with locally advanced or metastatic EGFR-mutated NSCLC who have received previous EGFR-targeted therapy and platinum-based chemotherapy. Program faculty:Allison Butts, PharmD, BCOPPharmacist Manager, OncologyClinical Pharmacist, Breast OncologyUK HealthCareMarkey Cancer CenterLexington, KentuckyDanielle Roman, PharmD, BCOPManager, Oncology Clinical Pharmacy ServicesAllegheny Health NetworkPittsburgh, PennsylvaniaProgram page:https://bit.ly/4lr7cT6

This week's Grocery Guys podcast reveals how the rapidly expanding wholesale distributor, with SpartanNash in its sights, is reshaping the grocery landscape

What are the the Psalms of Ascent? Why are they significant to God's people? Today, Emma Dotter talks with Watermark member, Bri Carlisle about Psalms 120-130 and the journey that God's people made to Jerusalem where they would sing these Psalms. Bri reminds us that these Psalms point to the never changing character of God and his love for us, even when we don't deserve it. Respond in worship with Psalm 130 by Shane and Shane: https://www.youtube.com/watch?app=desktop&v=l8pCbtLeXzc&t=32m39s

Tyler Andrews is a good friend with whom I've done trips with to Peru, Ecuador, and most recently, the Atacama Desert of Chile where we climbed up to almost 20,000 feet.  Ty was a self-described high school nerd musician who went on to be an average D3 cross country runner. After battling depression, Ty dedicated himself to becoming a pro mountain runner, which has seen him set numerous FKTs on some of the most iconic tall peaks in the world, including Aconcagua, Kilimanjaro, and Cotopaxi. One recent FKT in the Himalayas has been commemorated in the very cool short film “9 Hours on Manaslu” that you can watch on YouTube and is definitely worth 27 minutes of your time. To show his breadth, Ty also holds the record for the Leadville Marathon and has run in the U.S. Olympic marathon trials. He is a La Sportiva-sponsored athlete and is founder of the Chaski Endurance Collective, which coaches ultramarathoners. Which all leads us to this riveting WASP appearance, on which we chat about his recent attempts to set the FKT for running up Mt. Everest, both with and without supplemental oxygen. How incredible does that sound? I won't ruin the story for you, but Ty will talk about the what, when, how, and why for this audacious project and all of the logistics and challenges involved. For some really great content that gets very granular about how Ty did this, I highly recommend you go listen to his 21-part podcast series called Ty's Training: Talking with my Dad.  It's fascinating hearing some of the innovative methods Ty used to train for this quest that pushed him harder than he's ever been challenged before. I'm sure you'll love this story.Tyler Andrews:Facebook Tyler Andres AndrewsInstagram and Twitter: @tylercandrewsChaski Endurance Collective:www.chaski.run/linktreeInstagram: @chaski.enduranceBill Stahlsilly_billy@msn.comFacebook Bill StahlInstagram and Threads @stahlor and @we_are_superman_podcastYouTube We Are Superman PodcastPlease support Team Leadville and Warriors' Ascent help prevent veteran suicide! Donate here:https://give.classy.org/BillStahl2025Thank you!Subscribe to the We Are Superman Newsletter!https://mailchi.mp/dab62cfc01f8/newsletter-signupSubscribe to our Substack for my archive of articles of coaching tips developed from my more than three decades of experience, wild and funny stories from my long coaching career, the wit and wisdom of David, and highlights of some of the best WASP episodes from the past that I feel are worthwhile giving another listen.Search either We Are Superman Podcast or @billstahl8

Have you ever felt like you may worry about things greater than you are? Welcome to the club!Join us this week and learn what Pastor David shares with us from a teaching from the Psalm of Ascent.Do you have a question about our teaching series that you would like answered? ⁠Submit it here!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ About Music Track: Track: Inspirational Flight Artist: AShamaluevMusic Owner: Aleksandr Shamaluev.

Taylor and Jose are Joined by Taylor Abaroa to launch a new series and to look at how we can process and take our stress to the Lord.

Psalms 120 & 121 from the Psalms of Ascent, Ascending with Christ. Sermon Notes & Liturgy Summer Reading Guide Christ City Church, Dallas, Texas June 22nd, 2025

Dr. Allison Zibelli and Dr. Rebecca Shatsky discuss advances in breast cancer research that were presented at the 2025 ASCO Annual Meeting, including a potential new standard of care for HER2+ breast cancer, the future of ER+ breast cancer management, and innovations in triple negative breast cancer therapy. Transcript Dr. Allison Zibelli: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Allison Zibelli, your guest host of the podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. There was a substantial amount of exciting breast cancer data presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Rebecca Shatsky today to discuss some of these key advancements. Dr. Shatsky is an associate professor of medicine at UC San Diego and the head of breast medical oncology at the UC San Diego Health Moores Cancer Center, where she also serves as the director of the Breast Cancer Clinical Trials Program and the Inflammatory and Triple-Negative Breast Cancer Program.  Our full disclosures are available in the transcript of this episode. Dr. Shatsky, it's great to have you on the podcast today. Dr. Rebecca Shatsky: Thanks, Dr. Zibelli. It's wonderful to be here. Dr. Allison Zibelli: So, we're starting with DESTINY-Breast09, which was trastuzumab deruxtecan and pertuzumab versus our more standard regimen of taxane, trastuzumab pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. Could you tell us a little bit about the study? Dr. Rebecca Shatsky: Yeah, absolutely. So, this was a long-awaited study. When T-DXd, or trastuzumab deruxtecan, really hit the market, a lot of these DESTINY-Breast trials were started around the same time. Now, this was a global, randomized, phase 3 study presented by Dr. Sara Tolaney from the Dana-Farber Cancer Institute of Harvard in Boston. It was assessing essentially T-DXd in the first-line setting for metastatic HER2-positive breast cancer in addition to pertuzumab. And that was randomized against our standard-of-care regimen, which was established over a decade ago by the CLEOPATRA trial, and we've all been using that internationally for at least the past 10 years. So, this was a large trial, and it was one-to-one-to-one of patients getting T-DXd plus pertuzumab, T-DXd alone, or THP, which mostly is used as docetaxel and trastuzumab and pertuzumab every three weeks for six cycles. And this was in over 1,000 patients; it was 1,159 patients with metastatic HER2-positive breast cancer. This was a very interesting trial. It was looking at the use of trastuzumab deruxtecan, but patients were started on this treatment for their first-line metastatic HER2-positive breast cancer with no end date to their T-DXd. So, it was, you know, you were started on T-DXd every 3 weeks until progression. Now, CLEOPATRA is a little bit different than that, though, as we know. So, CLEOPATRA has a taxane plus trastuzumab and pertuzumab. But generally, patients drop the taxane after about six to seven cycles because, as we know, you can't be really on a taxane indefinitely. You get pretty substantial neuropathy as well as cytopenias, other things that end up happening. And so, in general, that regimen has sort of a limited time course for its chemotherapy portion, and the patients maintained after the taxane is dropped on their trastuzumab and their pertuzumab, plus or minus endocrine therapy if the investigator so desires. And the primary endpoint of the trial was progression-free survival by blinded, independent central review (BICR) in the intent-to-treat population. And then it had its other endpoints as overall survival, investigator-assessed progression-free survival, objective response rates, and duration of response, and of course, safety. As far as the results of this trial, so, I think that most of us key opinion leaders in breast oncology were expecting that this was going to be a positive trial. And it surely was. I mean, this is a really, really active drug, especially in HER2-positive disease, of course. So, the DESTINY-Breast03 data really established that, that this is a very effective treatment in HER2-positive metastatic breast cancer. And this trial really, again, showed that. So, there were 383 patients that ended up on the trastuzumab plus deruxtecan plus pertuzumab arm, and 387 got THP, the CLEOPATRA regimen. What was really interesting also to note of this before I go on to the results was that 52% of patients on this trial had de novo metastatic disease. And that's pretty unusual for any kind of metastatic breast cancer trial. It kind of shows you, though, just how aggressive this disease is, that a lot of patients, they present with de novo metastatic disease. It's also reflecting the global nature of this trial where maybe the screening efforts are a little bit less than maybe in the United States, and more patients are presenting as later stage because to have a metastatic breast cancer trial in the United States with 52% de novo metastatic disease doesn't usually happen. But regardless, the disease characteristics were pretty well matched between the two groups. 54% of the patients were triple positive, or you could say hormone-positive because whether they were PR positive or ER positive and PR negative doesn't really matter in this disease. And so, the interim data cutoff was February of this year, of 2025. So, the follow-up so far has been about 29 months, so the data is still really immature, only 38% mature for progression-free survival interim analysis. But what we saw is that T-DXd plus pertuzumab, it really improved progression-free survival. It had a hazard ratio that was pretty phenomenal at 0.56 with a confidence interval that was pretty narrow of 0.44 to 0.71. So, very highly statistically significant data here. The progression-free survival was consistent across all subgroups. Overall survival, very much immature at this time, but of course, the trend is towards an overall survival benefit for the T-DXd group. The median durable response with T-DXd plus pertuzumab exceeded 3 years. Now, importantly, though, I want to stress this, is grade 3 or above treatment-emergent adverse events occurred in both subgroups pretty equally. But there were 2 deaths in the T-DXd group due to interstitial lung disease. And there was a 12.1% adjudicated drug-induced interstitial lung disease/pneumonitis event rate in the T-DXd group and only 1%, and it was grade 1-2, in the THP group. So, that's really the caveat of this therapy, is we know that a percentage of patients are going to get interstitial lung disease, and that some may have very serious adverse events from it. So, that's always something I keep in the back of my mind when I treat patients with T-DXd. And so, overall, the conclusions of the trial were pretty much a slam dunk. T-DXd plus pertuzumab, it had a highly statistically significant and clinically meaningful improvement in progression-free survival versus the CLEOPATRA regimen. And that was across all subgroups for first-line metastatic HER2-positive breast cancer here. And so, yeah, the data was pretty impressive. Just to go into the overall response rate, because that's always super important as well, you had 85.1% of patients having a confirmed overall RECIST response rate in the T-DXd plus pertuzumab group and a 78.6 in the CLEOPATRA group. The complete CR rate, complete response was 15.1% in the T-DXd group and 8.5 in the CLEOPATRA regimen. And it was really an effective regimen in this group, of course. Dr. Allison Zibelli: So, the investigators say at the end of their abstract that this is the new standard of care. Would you agree with that statement? Dr. Rebecca Shatsky: Yeah, that was a bold statement to make because I would say in the United States, not necessarily at the moment because the quality of life here, you have to think really hard about. Because one thing that's really important about the DESTINY-Breast09 data is that this was very much an international trial, and in many of the countries where patients enrolled on this, they were not able to access T-DXd off trial. And so, for them, this means T-DXd now or potentially never. And so, that is a really big difference whereas internationally, that may mean standard of care. However, in the US, patients have no issues accessing T-DXd in the second- or third-line settings. And right now, it's the standard of care in the second line in the United States, with all patients basically getting this second-line therapy except for some unique patients where they may be doing a PATINA trial regimen, which we saw at San Antonio Breast Cancer in 2024 of the triple-positive patients getting hormonal therapy plus palbociclib, which had a really great durable response. That was super impressive as well. Or there is the patient that the investigator can pick KADCYLA because the patient really wants to preserve their hair or maybe it's more indolent disease. But the quality of life on T-DXd indefinitely in the first-line setting is a big deal because, again, that CLEOPATRA regimen allows patients to drop their chemotherapy component about five to six months in. And with this, you're on a drug that feels very chemo-heavy indefinitely. And so, I think there's a lot more to investigate as far as what we're going to do with this data in the United States because it's a lot to commit a patient in the first-line metastatic setting. These de novo metastatic patients, some of them may be cured, honestly, on the HER2-targeting regimen. That's something we see these days. Dr. Allison Zibelli: So, very interesting trial. I'm sure we'll be talking about this for a long time.  So, let's move on to SERENA-6, which was, I thought, a very interesting trial. This trial took patients with ER positive, advanced breast cancer after six months on an AI (aromatase inhibitor) and a CDK4/6 inhibitor. They did ctDNA every two to three months, and when they saw an ESR1 mutation emerge, they changed half of the patients to camizestrant plus CDK4/6 and kept the other half on the AI plus CDK4/6. Can you talk about that trial a little bit, please? Dr. Rebecca Shatsky: Yeah, so this was a big trial at ASCO25. This was presented as a Plenary Session. So, this was camizestrant plus a CDK4/6 inhibitor, and it could have been any of the three, so palbo, ribo, or abemaciclib in the first-line metastatic hormone-positive population, and patients were on an AI with that. They were, interestingly, tested by ctDNA at baseline to see if they had an ESR1 mutation. So, that was an interesting feature of this trial. But patients had to have already been on their CDK4/6 inhibitor plus AI for at least 6 months to enroll. And then, as you mentioned, they got ctDNA testing every 2 to 3 months. This was also a phase 3, double-blind, international trial. And I do want to highlight again, international here, because that's important when we're considering some of this data in the U.S. because it influences some of the results. So, this was presented by Dr. Nick Turner of the Royal Marsden in the UK. So, just a little bit of background for our listeners on ESR1 mutations and why they're important. This is the most common, basically, acquired resistance mutation to patients being treated with aromatase inhibitors. We know that treatment with aromatase inhibitors can induce this. It makes a conformational change in the estrogen receptor that makes the estrogen receptor constitutively active, which allows the cell to signal despite the influence of the aromatase inhibitor to decrease the estrogen production so that the ligand binding doesn't matter as much as far as the cell signaling and transcription is concerned. And camizestrant, you know, as an oral SERD, just to explain that a little bit too; these are estrogen receptor degraders. The first-in-class of a selective estrogen receptor degrader to make it to market was fulvestrant. And that's really been our standard-of-care estrogen degrader for the past 25 years, almost 25 years. And so, a lot of us are just looking for some of these oral SERDs to replace that. But regardless, they do tend to work in the ESR1-mutated population. And we know that patients on aromatase inhibitors, the estimates of patients developing an ESR1 mutation, depending on which study you look at, somewhere between 30% to 50% overall, patients will develop this mutation with hormone-positive metastatic breast cancer. There is a small percentage of patients that have these at baseline without even treatment of an aromatase inhibitor. The estimates of that are somewhere between 0.5 and up to 5%, depending on the trial you look at and the population. But regardless, there is a chance someone on their CDK4/6 inhibitor plus AI at 6 months' time course could have had an ESR1 mutation at that time. But anyway, so they got this ctDNA every 2 to 3 months, and once they were found to develop an ESR1 mutation, the patients were then switched to the oral SERD. AstraZeneca's version of the oral SERD is camizestrant, 75 mg daily. And then their type of CDK4/6 inhibitor was maintained, so they didn't switch the brand of their CDK4/6 inhibitor, importantly. And that was looked at then for progression-free survival, but these were patients with measurable disease by RECIST version 1.1. And the data cut off here was November of 2024. This was a big trial, you know, and I think that that's influential here because this was 3,256 patients, and that's a lot of patients. So, they were all eligible. And then 315 patients ended up being randomized to switch to camizestrant upon presence of that ESR1 mutation. So, that was 157 patients. And then the other half, so they were randomized 1:1, they continued on their AI without switching to an oral SERD. That was 158 patients. They were matched pretty well. And so, their baseline characteristics, you know, the two subgroups was good. But this was highly statistically significant data. I'm not going to diminish that in any way. Your hazard ratio was 0.44. Highly statistically significant confidence intervals. And you had a median progression-free survival in those that switched to camizestrant of 16 months, and then the non-switchers was 9.2 months. So, the progression-free survival benefit there was also consistent across the subgroups. And so, you had at 12 months, the PFS rate was 60.7% for the non-treatment group and 33.4% in the treatment group. What's interesting, though, is we don't have overall survival data. This is really immature, only 12% mature as far as overall survival. And again, because this was an international trial and patients in other countries right now do not have the access to oral SERDs that the United States does, the crossover rate, they were not allowed to crossover, and so, a very few patients, when we look at progression-free survival 2 and ultimately overall survival, were able to access an oral SERD in the off-trial here and in the non-treatment group. And so, that's really important as far as we look at these results. Adverse events were pretty minimal. These are very safe drugs, camizestrant and all the other oral SERDs. They have some mild toxicities. Camizestrant is known for something weird, which is called photopsia, which is some flashing lights in the periphery of the eye, but it doesn't seem to have any serious clinical significance that we know of. It has a little bit of bradycardia, but it's otherwise really well tolerated. You know, I hate to say that because that's very subjective, right? I'm not the one taking the drug. But it doesn't have any serious adverse events that would cause discontinuation. And that's really what we saw in the trial. The discontinuation rates were really low. But overall, I mean, this was a positive trial. SERENA-6 showed that switching to camizestrant at the first sign of an ESR1 mutation on CDK4/6 inhibitor plus AI improved progression-free survival. That's all we can really say from it right now. Dr. Allison Zibelli: So, let's move on to ASCENT-04, which was a bit more straightforward. Sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in PD-L1-positive, triple-negative breast cancer. Could you talk about that study? Dr. Rebecca Shatsky: Yeah, so this was also presented by the lovely Sara Tolaney from Dana-Farber. And this study made me really excited. And maybe that's because I'm a triple-negative breast cancer person. I mean, not to say that I don't treat hundreds of patients with hormone- positive, but our unmet needs in triple negative are huge because this is a disease where you have got to throw your best available therapy at it as soon as you can to improve survival because survival is so poor in this disease. The average survival with metastatic triple-negative breast cancer in the United States is still 13-18 months, and that's terrible. And so, for full disclosure, I did have this trial open at my site. I was one of the site PIs. I'm not the global PI of the study, obviously. So, what this study was was for patients who had had at least a progression-free survival of 6 months after their curative intent therapy or de novo metastatic disease. They were PD-L1 positive as assessed by the Dako 22C3 assay of greater than or equal to a CPS score of 10. So, that's what the KEYNOTE-355 trial was based on as well. So, standard definition of PD-L1 positive in breast cancer here. And basically, these patients were randomized 1:1 to either their sacituzumab govitecan plus pembrolizumab, day 1 they got both therapies, and then day 8 just the saci, as is standard for sacituzumab. And then the other group got the KEYNOTE-355 regimen. So, that is pembrolizumab with – your options are carbogem there, paclitaxel or nab-paclitaxel. And it's up to investigator's decision which upon those they decided. They followed these patients for disease progression or unacceptable toxicity. It was really an impressive trial in my opinion because we know already that this didn't just improve progression-free survival, because survival is so poor in this disease, of course, we know that it improved overall survival. It's trending towards that very much, and I think that's going to be shown immediately. And then the objective response rates were better, which is key in this disease because in the first-line setting, you've got a lot of people who, especially your relapsed TNBC that don't respond to anything. And you lose a ton of patients even in the first-line setting in this disease. And so, this was 222 patients to chemotherapy and pembro and 221 to sacituzumab plus pembro. Median follow-up has only been 14 months, so it's still super early here. Hazard ratio so far of progression-free survival is 0.65, highly statistically significant, narrow confidence intervals. And so, the median duration of response here for the saci group was 16.5 months versus 9.2 months. So, you're getting a 7-month progression-free survival benefit here, which in triple negative is pretty fantastic. I mean, this reminds me of when we saw the ASCENT data originally come out for sacituzumab, and we were all just so happy that we had this tool now that doubled progression-free and overall survival and made such a difference in this really horrible disease where patients do poorly. So, OS is technically immature here, but it's really trending very heavily towards improvement in overall survival. Importantly, the treatment-related adverse events in this, I mean, we know sacituzumab causes neutropenia, people who are experienced with this drug know how to manage it at this point. There wasn't any really unexpected treatment-related adverse events. You get some people with sacituzumab who have diarrhea. It's usually pretty manageable with some Imodium. So, it was cytopenias predominantly in this disease in this population that were highlighted as far as adverse events. But I'm going to be honest, like I was surprised that this wasn't the plenary over the SERENA-6 data because this, in my mind, there we have a practice-changing trial. I will immediately be trying to use this in my PD-L1 population because, to be honest, as a triple-negative breast cancer clinical specialist, when I get a patient with metastatic triple-negative breast cancer who's PD-L1 positive, I think, "Oh, thank God," because we know that part of the disease just does better in general. But now I have something that really could give them a durable response for much longer than I ever thought possible when I started really heavily treating this disease. And so, this was immediately practice-changing for me. Dr. Allison Zibelli: I think that it's pretty clear that this is at least an option, if not the option, for this group of patients. Dr. Rebecca Shatsky: Yeah, the duration of responses here was – it's just really important because, I mean, I do think this will make people live longer. Dr. Allison Zibelli: So, moving on to the final study that we're going to discuss today, neoCARHP (LBA500), which was neoadjuvant taxane plus trastuzumab, pertuzumab, plus or minus carbo(platin) in HER2-positive early breast cancer. I think this is a study a lot of us have been waiting for. What was the design and the results of this trial? Dr. Rebecca Shatsky: I was really excited about this as well because I'm one of those people that was waiting for this. This is a Chinese trial, so that is something to take note of. It wasn't an international trial, but it was a de-escalation trial which had become really popular in HER2-positive therapy because we know that we're overtreating HER2-positive breast cancer in a lot of patients. A lot of patients we're throwing the kitchen sink at it when maybe that is not necessary, and we can really de-escalate and try to personalize therapy a little bit better because these patients tend to do well. So, the standard of care, of course, in HER2-positive curative intent breast cancer with tumors that are greater than 2 cm is to give them the TCHP regimen, which is docetaxel, carboplatin, trastuzumab, and pertuzumab. And that was sort of established by several trials in the NeoSphere trial, and now it's been repeated in a lot of different studies as well. And so, that's really the standard of care that most people in the United States use for HER2-positive curative intent breast cancer. This was a trial to de-escalate the carboplatin, which I was super excited about because many of us who treat this disease a lot think carbo is the least important part of the therapy you're giving there. We don't really know that it's necessary. We've just been doing it for a long time, and we know that it adds a significant amount of toxicity. It causes thrombocytopenia, it causes severe nausea, really bad cytopenias that can be difficult in the last few cycles of this to manage. So, this trial was created. It randomized patients one to one with stage 2 and 3 HER2-positive breast cancer to either get THP, a taxane, pertuzumab, trastuzumab, similar to the what we do in first-line metastatic HER2-positive versus the whole TCHP with a carboplatin AUC of 6, which is what's pretty standard. And it was a non-inferiority trial, so important there. It wasn't to establish superiority of this regimen, which none of us, I think, were looking for it to. And it was a modified intent-to-treat population. And so, all patients got at least one cycle of this to be assessed as a standard for an intent-to-treat trial. And so, they assumed a pCR rate of about 62.8% for both groups. And, of course, it included both HER2-positive triple positives and ER negatives, which are, you know, a bit different diseases, to be honest, but we all kind of categorize them and treat them the same. And so, this trial was powered appropriately to detect a non-inferiority difference. And so, we had about 380 patients treated on both arms, and there was an absolute difference of only 1.8% of those treated with carbo versus those without. Which was fantastic because you really realized that de-escalation here may be something we can really do. And so, the patients who got, of course, the taxane regimen had fewer adverse events. They had way fewer grade 3 and 4 adverse events than the THP group. No treatment-associated deaths occur, which is pretty standard for- this is a pretty safe regimen, but it causes a lot of hospitalizations due to diarrhea, due to cytopenias, and neutropenic fever, of course. And so, I thought that this was something that I could potentially enact, you know, and be practice-changing. It's hard to say that when it's a trial that was only done in China, so it's not necessarily the United States population always. But I think for patients moving forward, especially those with, say, a 2.5 cm tumor, you know, node negative, those, I'd feel pretty comfortable not giving them the carboplatin here. Notes that I want to make about this population is that the majority were stage 2 and not stage 3. They weren't necessarily your inflammatory HER2-positive breast cancer patients. And that the taxane that was utilized in the trial is a little different than what we use in the United States. The patients were allowed to get nab-paclitaxel, which we don't have FDA approval for in the first-line curative intent setting for HER2-positive breast cancer in the United States. So, a lot of them got abraxane, and then they also got paclitaxel. We tend to use docetaxel every 3 weeks in the United States. So, just to point out that difference. We don't really know if that's important or not, but it's just a little bit different to the population we standardly treat. Dr. Allison Zibelli: So, are there patients that you would still give TCHP to? Dr. Rebecca Shatsky: Yeah, great question. I've been asked that a lot in the past like week since ASCO. I'd say in my inflammatory breast cancer patients, that's a group I do tend to sometimes throw the kitchen sink at. Now, I don't actually use AC in those because I know that that was the concern, but I think the TRAIN-2 trial really showed us you don't need to use Adriamycin in HER2-positive disease unless it's like refractory. So, I don't know that I would throw this on my stage 3C or inflammatory breast cancer patients yet because the majority of this were not stage 3. So, in your really highly lymph node positive patients, I'm a little bit hesitant to de-escalate them from the start. This is more of a like, if there's serious toxicity concerns, dropping carbo is absolutely fine here. Dr. Allison Zibelli: All right, great.  Thank you, Dr. Shatsky, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Rebecca Shatsky: Thanks so much, Dr. Zibelli and ASCO Daily News. I really want to thank you for inviting me to talk about this today. It was really fun, and I hope you find my opinions on some of this valuable. And so, I just want to thank everybody and my listeners as well. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you learn things from it, please take a moment to rate, review, and describe because it helps other people find us wherever you get your podcasts. Thank you again. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers Dr. Allison Zibelli Dr. Rebecca Shatsky @Dr_RShatsky Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn   Disclosures: Dr. Allison Zibelli: No relationships to disclose Dr. Rebecca Shatsky: Consulting or Advisory Role: Stemline, Astra Zeneca, Endeavor BioMedicines, Lilly, Novartis, TEMPUS, Guardant Health, Daiichi Sankyo/Astra Zeneca, Pfizer Research Funding (Inst.): OBI Pharma, Astra Zeneca, Greenwich LifeSciences, Briacell, Gilead, OnKure, QuantumLeap Health, Stemline Therapeutics, Regor Therapeutics, Greenwich LifeSciences, Alterome Therapeutics  

Pastor Jose launches a new series called the "Songs of Ascent" looking at the book of Psalms.

In this episode of Arise + Abide, Sally and Curtis reflect on Psalm 120, the first of the Psalms of Ascent. They explore how this cry for rescue from lies and conflict becomes a model of trust in God's faithfulness. As the psalmist laments the struggle to live among those who hate peace, Sally and Curtis share personal insights on surrendering burdens to God, trusting Him to handle deceit and injustice, and finding lasting peace in His presence. With encouragement from Philippians 4, they remind us that true peace is not found in the absence of trouble but in continual prayer and deep reliance on God's steadfast love.

This six-week series looks at the Psalms of Ascent to learn what they can teach us about God and community. We hope that this ministry has blessed you in some way and that you would consider liking, subscribing, and sharing this channel with your friends, family, or a person God has placed on your heart. As always if you would like prayer please Text “Prayer” to 561.867.3400 and if you've made a decision to follow Christ today  or have more questions would you please consider  texting the word “Decided” to 561.867.3957  so that we can pray with you and provide you with  some resources to begin your journey with the Savior. Have a blessed day your family @ FBC Lantana Connect Card: Text "Connect" to 561.867.3353 Prayer Request: Text “Prayer” to 561.867.3400 I have decided to follow Jesus: Text “Decided” to 561.867.3957

Join us as we continue our Summer teaching series

Dylan sits down with Anna Gibson (Brooks) for a post-race interview after her incredible win today at the Broken Arrow Ascent. Anna has quickly made a name for herself, winning major short distance trail races like the Gorge Waterfalls 30k and Sunapee Scramble. She'll be headed to Spain in September to represent Team USA in two distances: The Uphill and The Classic.   Our Broken Arrow coverage is brought to you by our good friends at HOKA. We're grateful for their generous support and belief in Freetrail.   Make sure to check out the latest and greatest from HOKA, the Mafate X. The Mafate X is all about innovation and pushing past limits. HOKA evolved their max-cushion trail experience to provide the confidence, control, and adaptability ultra runners require for their biggest trail efforts. Embracing the paradox of max cushion and stability on trail to develop a new experience for the longest adventures.    You can learn more and shop here: https://www.hoka.com/en/us/mafate/   Freetrail Links:  Website | https://freetrail.com/ Freetrail Pro | https://freetrail.com/pro/ Patreon |   / dylanbowman   Instagram | https://www.instagram.com/runfreetrai... YouTube |    / @freetrail   Freetrail Experts | https://freetrail.com/experts/   Dylan Links:  Instagram | https://www.instagram.com/dylanbo/?hl=en Twitter | https://twitter.com/dylanbo?lang=en LinkedIn |   / dylan-bowman-06174380  

Dylan sits down with Christian Allen (Nike) for a post-race interview after his incredible win today at the Broken Arrow Ascent. Christian is a mountain athlete, 2:10 marathoner, and loving dad of 3 with number 4 on the way.  

   Christian will be headed to Spain in September to represent Team USA for the first time, racing the Uphill. In addition to worlds, he has a stacked racing calendar lined up for the fall, tune in to hear his plans.   Our Broken Arrow coverage is brought to you by our good friends at HOKA. We're grateful for their generous support and belief in Freetrail.   Make sure to check out the latest and greatest from HOKA, the Mafate X. The Mafate X is all about innovation and pushing past limits. HOKA evolved their max-cushion trail experience to provide the confidence, control, and adaptability ultra runners require for their biggest trail efforts. Embracing the paradox of max cushion and stability on trail to develop a new experience for the longest adventures.    You can learn more and shop here: https://www.hoka.com/en/us/mafate/   Freetrail Links:  Website | https://freetrail.com/ Freetrail Pro | https://freetrail.com/pro/ Patreon |   / dylanbowman   Instagram | https://www.instagram.com/runfreetrai... YouTube |    / @freetrail   Freetrail Experts | https://freetrail.com/experts/   Dylan Links:  Instagram | https://www.instagram.com/dylanbo/?hl=en Twitter | https://twitter.com/dylanbo?lang=en LinkedIn |   / dylan-bowman-06174380  

Dylan sits down with Joe Gray (HOKA) for a post-race interview after his incredible performance at the Broken Arrow Ascent. Joe placed second, proving he is still on top of his game and one of the best in the world. Joe punched his ticket to worlds for team USA for the 17th year in a row, so unbelievably impressive. Our Broken Arrow coverage is brought to you by our good friends at HOKA. We're grateful for their generous support and belief in Freetrail.   Make sure to check out the latest and greatest from HOKA, the Mafate X. The Mafate X is all about innovation and pushing past limits. HOKA evolved their max-cushion trail experience to provide the confidence, control, and adaptability ultra runners require for their biggest trail efforts. Embracing the paradox of max cushion and stability on trail to develop a new experience for the longest adventures.    You can learn more and shop here: https://www.hoka.com/en/us/mafate/   Freetrail Links:  Website | https://freetrail.com/ Freetrail Pro | https://freetrail.com/pro/ Patreon |   / dylanbowman   Instagram | https://www.instagram.com/runfreetrai... YouTube |    / @freetrail   Freetrail Experts | https://freetrail.com/experts/   Dylan Links:  Instagram | https://www.instagram.com/dylanbo/?hl=en Twitter | https://twitter.com/dylanbo?lang=en LinkedIn |   / dylan-bowman-06174380   Strava |   / strava    

Thanks for tuning into Freetrail's coverage of the 2025 Broken Arrow Skyrace! We'll be live every day starting Thursday June 19th through Sunday June 22nd starting at 3:30pm PT.   In today's show hosted by Dylan Bowman and EmKay Sullivan, we host interviews with women's 2nd place finisher Joyce Njeru (Nnormal), 3rd place Jade Belzberg (Altra) and men's 4th place finisher Tyler McCandless. Dylan and EmKay then recap the Ascent, talk about EmKay's race and preview Saturday's 46k. For interviews with the women's champion Anna Gibson, men's champion Christian Allen, and men's 2nd place finisher Joe Gray, please check out those standalone interviews on the Freetrail YouTube.   What was your favorite performance from the Ascent? Whose your pick for the 46k tomorrow? Let us know in the comments!   Want to learn more about Freetrail? Check out Freetrail.com to learn more and consider joining our membership community, Freetrail Pro, to be part of the best global online community of passionate trail runners. Best sport in the world! Make sure to play Freetrail's own fantasy trail running at https://fantasy.freetrail.com/events.   Don't forget to pick your favorite athletes in Freetrail Fantasy at fantasy.freetrail.com for your chance to win sweet prizes!   Our Broken Arrow coverage is brought to you by our good friends at HOKA. We're grateful for their generous support and belief in Freetrail.   Make sure to check out the latest and greatest from HOKA, the Mafate X. The Mafate X is all about innovation and pushing past limits. HOKA evolved their max-cushion trail experience to provide the confidence, control, and adaptability ultra runners require for their biggest trail efforts. Embracing the paradox of max cushion and stability on trail to develop a new experience for the longest adventures.    You can learn more and shop here: https://www.hoka.com/en/us/mafate/   Freetrail Links:  Website | https://freetrail.com/ Freetrail Pro | https://freetrail.com/pro/ Patreon |   / dylanbowman   Instagram | https://www.instagram.com/runfreetrai... YouTube |    / @freetrail   Freetrail Experts | https://freetrail.com/experts/   Dylan Links:  Instagram | https://www.instagram.com/dylanbo/?hl=en Twitter | https://twitter.com/dylanbo?lang=en LinkedIn |   / dylan-bowman-06174380   Strava |   / strava    

Read OnlineJesus said to his disciples: “No one can serve two masters. He will either hate one and love the other, or be devoted to one and despise the other. You cannot serve God and mammon.” Matthew 6:24Mammon is another word for money. Jesus is clear that you must choose to serve either God or money, but not both. A divided heart does not suffice. Saint John of the Cross, in His spiritual classic “Ascent to Mount Carmel,” explains something similar. He says that our desires must become completely purified to the point that all we desire is God and His holy will. Every other desire in life must be purged away so that we are singularly devoted to God. Does this mean that God and God alone should be the object of all of our love? Yes, indeed. But that truth must be properly understood.When we consider the calling we have been given from God to love, it is true that we must love not only God but also many other things in life. We must love family, friends, neighbors, and even our enemies. Hopefully we also love other aspects of our lives, such as our vocation, our job, our home, a certain pastime, etc. So how do we love God with singular devotion when we also have many other things we must love?The answer is quite simple. The love of God is such that when we make God the singular object of our love and devotion, the love we have for God will supernaturally overflow. This is the nature of the love of God. As we love God, we will find that God calls us to love Him by loving other people and even various aspects of our lives. As we love what God wills us to love and as we express our love for all that is contained in the will of God, we are still loving God with all our heart, mind, soul and strength.But back to our Scripture above. Why is it that we cannot love God and money? “Mammon” in this passage must be understood as a love that becomes an unhealthy attachment and desire. Money is such that we can “love” it by allowing our desires for it to become disordered and, thus, exclude the will of God from that “love.” Money is not evil when it is used solely in accord with the will of God. In that case, the money we use will give God great glory. But when money, or any other object of our desire, begins to take on a life of its own, so to speak, then that desire will be at odds with our love of God. To love God and God alone means we love God and all that He wills us to love in life.Reflect, today, upon the necessity of being singularly devoted to God. As you commit yourself to this exclusive love, consider also whom and what God calls you to love in and through Him. Where does His perfect will lead you, and how are you called to show your love of God through the love of others? Consider, also, any ways in which you have allowed an unhealthy attachment to money or anything else in life to distract you from the one and ultimate purpose of your life. Allow God to purge those unhealthy desires and false “loves” from your heart so that you will be free to love as you were made to love.My Lord and God, You are worthy of all of my love. You and You alone must become the single focus of all of my love. As I love You, dear Lord, help me to discover all that Your will directs me to love more and all that Your will calls me to detach from. May I choose only You and that which is contained in Your holy and perfect will. Jesus, I trust in You.Image: James Tissot, Public domain, via Wikimedia CommonsSource of content: catholic-daily-reflections.comCopyright © 2025 My Catholic Life! Inc. All rights reserved. Used with permission via RSS feed.

Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Erika Hamilton from the Sarah Cannon Research Institute to discuss the latest breakthroughs in breast cancer presented at the ASCO 2025 annual meeting. We dived into five key abstracts that could change the landscape of breast cancer treatment: 1.⁠ INAVO120: observed overall survival data with the combination of inavolisib, with palbociclib and fulvestrant for patients with PIK3CA mutated hormone receptor-positive, HER2-negative advanced breast cancer. 2.⁠ ⁠SERENA-6: camizestrant use in patients with emerging ESR1 mutations using ctDNA, showed significant improvement in progression-free survival. 3.⁠ ⁠VERITAC-2: vepdegestrant showed superior progression-free survival compared to fulvestrant, particularly in ESR1 mutated patients. 4.⁠ ⁠DESTINY-Breast09: significant improvement in progression-free survival with TDXd plus pertuzumab in frontline HER2-positive metastatic breast cancer, challenging the traditional CLEOPATRA regimen THP. 5.⁠ ⁠ASCENT-04: promising results of sacituzumab combined with pembrolizumab in PD-L1 positive triple-negative breast cancer. Join us for an insightful discussion on these practice changing/informing studies and their implications for clinical practice.  YouTube: https://youtu.be/5XvrOn2p0jc Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more updates on treatment algorithms, recent approvals, and conference highlights!

Berkshire Hathaway's shares nosedive—what's behind the biggest drop in over a decade? Michelle Martin and Ryan Huang unpack how oil spikes create winners and losers. Airbus soars with a blockbuster showing at the Paris Air Show, while Boeing stumbles. Can ExxonMobil and United Airlines ride the energy wave? Singapore's STI edges up—what are the levels to watch today? Hosted by Michelle Martin with Ryan Huang. Companies mentioned: Berkshire Hathaway, Airbus, Boeing, ExxonMobil, United Airlines, DBS, Keppel Corp, Singapore Airlines (SIA)See omnystudio.com/listener for privacy information.

Click here for the DRB Daily Sign Up form! TODAY'S SCRIPTURE: 2 Kings 1-3; Psalm 82; 1 Timothy 1 Click HERE to give! Get Free App Here! One Year Bible Podcast: Join Hunter and Heather Barnes on 'The Daily Radio Bible' for a daily 20-minute spiritual journey. Engage with scripture readings, heartfelt devotionals, and collective prayers that draw you into the heart of God's love. Embark on this year-long voyage through the Bible, and let each day's passage uplift and inspire you. TODAY'S EPISODE: Welcome to the Daily Radio Bible! In today's episode, join Hunter as we journey together through the Bible on this 19th day of June. We'll dive into the dramatic stories of Second Kings chapters 1-3, witness Elijah's fiery encounters and miraculous departure, and see Elisha step into his prophetic calling. We'll also spend time in Psalm 82, where God calls us to justice and compassion, and move into the New Testament with First Timothy chapter 1, where Paul reminds us not to miss the heart of the gospel—a life transformed by love, pure conscience, and genuine faith. Hunter shares encouraging reflections on letting God's Spirit shape us from the inside out, rather than getting lost in meaningless debates or empty rule-keeping. We'll close with heartfelt prayers for peace, gratitude, and strength for the day ahead. So grab your Bible, take a deep breath, and let's immerse ourselves in God's Word and presence together. TODAY'S DEVOTION: Don't Miss the Point We are so prone to miss the point when we misapply the law. It can lead us into a life of pride and arrogance or self-loathing and despair. Engaging with the law in this way, as Hunter reminds us, can become a colossal exercise in missing the point. When we seek to justify ourselves by keeping the law or becoming experts in its letters, we actually miss the underlying message and purpose. That's exactly what Paul points out in his letter to Timothy—some people have veered from the simple truth, spending their days in meaningless discussions that add nothing to a life of faith (see 1 Timothy 1:6). They had turned away from the simple gospel, the good news that is received by faith and fills our hearts with love, cleanses our conscience, and makes us new. Paul reemphasizes this in verse 5: “The purpose of my instruction is that all believers would be filled with love that comes from a pure heart, a clear conscience, and genuine faith.” This, Hunter says, is the real deal—this is the point. This is the work that God alone can do as his Spirit abides in his people. Through the Spirit's presence, God brings about a new heart, a clean conscience, and a new life. And we need to remember: that's a gift. It isn't something we can attain by mastering the law. True change comes not from our proficiency or expertise, but from the Master's presence in our lives. As we surrender, as we let the Master master us, God reclaims that which was lost. That's the power and the gift of the gospel, the very truth Paul is unashamed to proclaim. Living in the reality of Christ in you means you're not missing out on love, generosity, or peace—they are yours. And in receiving them, you'll have something beautiful to offer this world. That's a prayer Hunter has for his own soul, for his family, and for you: that we may not miss the point, but instead receive the love of God, a clean conscience, and a new life in Christ. May it be so. TODAY'S PRAYERS: Lord God Almighty and everlasting Father, you have brought us in safety to this new day. Preserve us with your mighty power that we might not fall into sin or be overcome by adversity. And in all we do, direct us to the fulfilling of your purpose. Through Jesus Christ our Lord. Amen. O God, you have made of one blood all the peoples of the earth and sent your blessed son to preach peace to those who are far and those who are near. Grant that people everywhere may seek after you and find you. Bring the nations into your fold. Pour out your spirit on all flesh and hasten the coming of your kingdom through Jesus Christ our Lord. Amen. And now, Lord, make me an instrument of your peace. Where there is hatred, let me sow love; where there is injury, pardon; where there is doubt, faith; where there is despair, hope; where there is darkness, light; and where there is sadness, joy. O Lord, grant that I might not seek so much to be consoled as to console, to be understood as to understand, to be loved as to love. For it is in the giving that we receive, in the pardoning that we are pardoned. It is in the dying that we are born unto eternal life. Amen. And now, as our Lord has taught us, we are bold to pray: Our Father, who art in heaven, hallowed be thy name. Thy kingdom come, thy will be done on earth as it is in heaven. Give us this day our daily bread and forgive us our trespasses as we forgive those who trespass against us. And lead us not into temptation, but deliver us from evil. For thine is the kingdom, and the power and the glory, forever and ever. Amen. OUR WEBSITE: www.dailyradiobible.com We are reading through the New Living Translation.   Leave us a voicemail HERE: https://www.speakpipe.com/dailyradiobible Subscribe to us at YouTube: https://www.youtube.com/@Dailyradiobible/featured OTHER PODCASTS: Listen with Apple Podcast DAILY BIBLE FOR KIDS DAILY PSALMS DAILY PROVERBS DAILY LECTIONARY DAILY CHRONOLOGICAL  

One of the most badass racers I know is Kat Edwards Anderson. She has been on the WASP twice before, most recently on episode #327 in January, chatting about her runs at the Sedona Canyons 125 and the Moab 240. I first met her in Chile in March, 2024, where she impressively conquered many new challenges for her in the high Atacama Desert. She built on these experiences by overcoming blisters on her feet, menstrual cycle irregularities, heat, and mental hurdles to get on the podium at Moab. In this episode, Kat shares some great insights on her run in May at the Cocodona 250, where she finished as the 6th female. Kat took many of the lessons from Moab, along with input from her coach, Tyler Andrews, to dial in the minutiae that is required to have success at such a grueling race. Kat shares much about the custom-designed gear she used to suit her needs, and the many very sound practices that she employed for Cocodona. Naturally, there were uncontrollables like the weather, and once again, her cycle. Most notably, she generously shares her mental battles through the race, and how her crew and her faith both came through for her to get to a finish line that at times seemed improbable. This is a great chat inside the mind of a tough, focused endurance beast of a runner. Next up for Kat is some “speedwork” as she comes out here to Colorado to slay the Leadville Trail 100.Kat Edwardskatedwardspt.comInstagram @kat.elizabeth_For coaching inquiries: www.chaski.runBill Stahlsilly_billy@msn.comFacebook Bill StahlInstagram and Threads @stahlor and @we_are_superman_podcastYouTube We Are Superman PodcastPlease support Team Leadville and Warriors' Ascent help prevent veteran suicide! Donate here:https://give.classy.org/BillStahl2025Thank you!Subscribe to the We Are Superman Newsletter!https://mailchi.mp/dab62cfc01f8/newsletter-signupSubscribe to our Substack for my archive of articles of coaching tips developed from my more than three decades of experience, wild and funny stories from my long coaching career, the wit and wisdom of David, and highlights of some of the best WASP episodes from the past that I feel are worthwhile giving another listen.Search either We Are Superman Podcast or @billstahl8

Sefer Bamidbar | Shelach | 5785 | The Meaning of Ascent, by Rav Ezra Bick

Send us a textWelcome to a special preview of what might be the most competitive mountain race ever assembled on American soil. As the Broken Arrow Skyrace approaches, we're diving deep into the Ascent competition (formerly known as the VK) where the stakes couldn't be higher – the top four American men and women will earn spots on Team USA for the World Mountain Running Championships.The star power in this year's field is simply astounding. Patrick Kipngeno returns to defend his title against an unexpected challenger – the legendary Killian Jornet, who's taking a detour from Western States preparation to test himself on American soil. Perhaps most exciting is the Broken Arrow debut of American mountain running GOAT Joe Gray, bringing decades of uphill expertise to a course that rewards pure running ability over hiking strength.On the women's side, we're witnessing what could be the making of a historic rivalry. Kenya's Joyce Njeru, undefeated in American races, faces rising star Anna Gibson, whose trajectory suggests she might become one of the all-time greats in mountain running. Veterans like Ali McLaughlin mix with breakthrough talents like Allie Ostrander and Oakley Olsen to create a fascinatingly deep field.We break down the modified course (3.61 miles with 2,840 feet of gain), analyze the key contenders, and make our predictions for both podium spots and Team USA qualification. The international talent is so strong that Americans might struggle to crack the top five, especially in the men's competition, making this one of the most compelling mountain races to watch this season.Whether you're filling out your FanTrail fantasy picks or simply wanting to understand the significance of this incredible event, our detailed preview gives you everything you need to appreciate the epic battle that's about to unfold on the slopes of Palisades Tahoe.Follow James on IG - @jameslaurielloFollow the Steep Stuff Podcast on IG - @steepstuff_podUse code steepstuffpod for 25% off your cart at UltimateDirection.com! 

PREVIEW MARS: Colleague Bob Zimmerman reports on the Curiosity images of the many odd, eery, sharo-toothed peaks it passes on the ascent of Mt. Sharp. More later. 1951

We interview author Carlos Martinez about China's economic system. He explains how China's unique path to modernity can inspire the world. Hosted on Acast. See acast.com/privacy for more information.

Dani and EmKay preview the Broken Arrow Ascent. This VK-like race is not only exciting for its international field, but it is also the US Team qualifier for the Vertical team at World Championships this year. Many US athletes will be doubling back from Sunapee to try to get their spots in a Team USA jersey. Kilian Jornet also highlights the field against 2 x world VK champion Patrick Kipgneno. Make sure you give this episode a listen before making your Freetrail Fantasy picks!Follow us:Instagram:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ @emkaysulli ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠| ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@dan_yell_a⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Podcast: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@the_subhub_pod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Title Picture Credit: Ryan ThrowerEpisode Sponsors:Neversecond: Use code SUBHUB25 for 25% off your purchase-- ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠never2.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Beekeepers Natural: Use code SUBHUB20 for 20% off your purchase-- ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.beekeepersnaturals.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Pit Viper:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Click this link for 20% off at checkout

Introductory sermon for our summer series in the Psalms of Ascent, Ascending with Christ. Acts 1: 3-12 Sermon Notes & Liturgy Summer Reading Guide Christ City Church, Dallas, Texas

This six-week series looks at the Psalms of Ascent to learn what they can teach us about God and community. We hope that this ministry has blessed you in some way and that you would consider liking, subscribing, and sharing this channel with your friends, family, or a person God has placed on your heart. As always if you would like prayer please Text “Prayer” to 561.867.3400 and if you've made a decision to follow Christ today  or have more questions would you please consider  texting the word “Decided” to 561.867.3957  so that we can pray with you and provide you with  some resources to begin your journey with the Savior. Have a blessed day your family @ FBC Lantana Connect Card: Text "Connect" to 561.867.3353 Prayer Request: Text “Prayer” to 561.867.3400 I have decided to follow Jesus: Text “Decided” to 561.867.3957

This is a classic WASP comeback story in a different kind of direction. Alex Neist is a former college and pro quarterback who seemingly had it all post-football – a thriving business career and great family – and then had it all fall apart because of his snoring. It's true, snoring. Alex found an unlikely answer with mouth taping, which he had to find on his own because he realized our healthcare system didn't espouse it because there isn't nearly the profit with it available to providers as, say, recommending meds or a CPAP machine. This kicked in his entrepreneurial spirit. Alex's philosophy toward starting a business is to identify a problem you're having and then provide a solution that others can also use to solve that issue. That led him to found Hostage Tape. He will explain to you why the provocative name. Alex says the change in one's sleep quality, and indeed in the quality of their life, is almost immediate when someone starts mouth taping. He also explains here why there is no reason to be concerned about not being able to breathe while using the product, and about a lot of other unexpected benefits that have made improvements in users' oral health, workouts, and yes, relationships. Hostage Tape now has hundreds of thousands of customers, some as well-known as Joe Rogan, and Alex's goal is to help one million people sleep better using Hostage Tape's products, which include nasal strips that have become all the rage these days for athletes, include many in the track world. Before you dismiss this as woo-woo stuff, definitely give this episode with Alex a listen – it will awaken you – or just the opposite of that – to a very simple, possibly life-changing, solution.Bill Stahlsilly_billy@msn.comFacebook Bill StahlInstagram and Threads @stahlor and @we_are_superman_podcastYouTube We Are Superman PodcastPlease support Team Leadville and Warriors' Ascent help prevent veteran suicide! Donate here:https://give.classy.org/BillStahl2025Thank you!Subscribe to the We Are Superman Newsletter!https://mailchi.mp/dab62cfc01f8/newsletter-signupSubscribe to our Substack for my archive of articles of coaching tips developed from my more than three decades of experience, wild and funny stories from my long coaching career, the wit and wisdom of David, and highlights of some of the best WASP episodes from the past that I feel are worthwhile giving another listen.Search either We Are Superman Podcast or @billstahl8

This is your ringside seat to the scorching hot Mets-Yankees rivalry, now that Juan Soto has shockingly joined the Queens contingent! Get ready for fiery debates, bold predictions, and no-holds-barred takes as we dissect the power shift, the simmering resentment from Yankee fans, and whether the Mets, with their newfound swagger and superstar, can finally claim supremacy in the greatest city in the world. This isn't just baseball; it's a New York inferno you won't want to miss!

>> https://emc2025.com/#tickets > https://givewheel.com/fundraising/6962/mission-everest/

Adam Green is a filmmaker, screenwriter, and horror icon best known for creating the Hatchet franchise and directing cult favorites like Frozen, Digging Up the Marrow, Spiral, Chillerama, and more. He is the co-host of The Movie Crypt podcast and founder of ArieScope Pictures.In this episode, Adam opens up about the brutal reality of filmmaking — from nearly walking away during the pandemic and the collapse of his dream project, Killer Pizza, to streaming platforms dismantling independent film. He shares personal stories of building a cult audience, the real reason Scary Sleepover disappeared from YouTube, and the constant battle to keep creative control. We also discuss the aftermath of the strike, censorship by the MPAA, and the madness of navigating Hollywood as an indie horror director.We talk origins of Hatchet, casting horror legends, the convention circuit, the return of slashers, and the death of physical media. Adam reflects on directing a younger cast in his upcoming film The Ascent, and shares untold stories about working with Tony Todd, Felissa Rose, Sid Haig, and the chaos of some of his most iconic films.Also covered: Yorkiethon 2025, the potential return of Scary Sleepover, social media controversies, Terrifier, cancel culture, and how horror has evolved in the age of streaming.—Subscribe: youtube.com/@TalksFromTheCryptFollow On Social Media –Talks From The Crypt: https://instagram.com/talksfromthecrypt / https://talksfromthecrypt.com Adam Green: https://www.instagram.com/adam_fn_greenYORKIETHON JULY 25-27, 2025: https://www.ariescope.comThe Movie Crypt Podcast: https://www.patreon.com/TheMovieCrypt—00:00:00 - Intro00:00:30 - The Movie Crypt Podcast, Wanting to Quit, Killer Pizza, Streaming vs. Physical Media, Pandemic Aftermath00:13:35 - The Reality of Filmmaking, Filming & Touring Hatchet and Frozen, Dealing With Critics00:20:47 - Holliston, Finding DP Will Barrett, First Feature Film, and Lessons In Actually Finishing What You Start00:29:32 - Writing, Working with Comedy, 48 Hour Live Stream, ArieScope's YouTube Channel - Halloween Shorts and Scary Sleepover00:39:48 - The Selection of Adam's Casts, Directing Performances, Working With a New Cast on 'Ascent', Being the "Old Guy" On Set00:53:44 - Casting Horror Icons, The Death and The Reviving of Slashers, Remakes & Reboots, Keeping Screenplays Private01:03:45 - Relinquishing Creative Control, Censorship, Trailers Spoiling the Film, Writing 'I, Survivor,' Writing Real Names Into Scripts01:15:11 - Vivid Detail in Writing, Digging Up The Marrow, Headaches of Distribution, Fan Letters and Theories01:47:16 - Using Practical FX, Final Destination, Bloodlines, Using Fears for Plots01:58:47 - Recasting Marybeth in Hatchet, Good Looking Casts, Filming Overseas in Malta, Grateful To Be a Filmmaker02:05:57 - The Strike and Pandemic's Effect on Hollywood, Damien Leone Twitter Controversy, Cancel Culture, and Social Media02:23:09 - Meeting Fans at Conventions, Tattoos, Being Lucky to Exist in Horror Culture, Bringing Back Scary Sleepover, Tony Todd, Sid Haig, and Making Friends With Anxiety02:38:19 - The Last Drive-In, Getting Booked at Conventions, Adam's Growth Since Hatchet 1, and Future Projects02:47:27 - Terrifier, MPAA's Censorship, Making Sequels02:54:28 - Horror Stories of Getting Recognized in Public, Yorkiethon, Gratitude for Horror Community03:03:19 - Adam Green's Social Media, Yorkiethon (JULY 25-27, 2025), and Outro—Copyright Disclaimer:Under section 107 of the Copyright Act 1976, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, education, and research. Fair use is a use permitted by copyright statute that might otherwise be infringing.

PREVIEW: Key Details of the Rocket Attacks When: Two rockets were fired from Syria into Israel on June 3, 2025, marking the first such attack since the fall of Bashar al-Assad's regime in December 2024 The Times of IsraelFDD. Target: The rockets were fired at the Golan Heights, landing in open areas near the community of Ramat Magshimim with no injuries reported Rockets fired from Syria for first time in a year; Israel holds Sharaa responsible | The Times of Israel. Two Terror Groups Responsible Ahmad Sharawi's FDD analysis identifies two distinct groups that claimed responsibility: 1. Mohammed Deif Brigades This group was reportedly founded on May 30, 2025, according to its Telegram channel and is named after the slain Hamas military chief Mohammad Deif, who was killed in July 2024 Syria Archives. The group first surfaced on social media just a few days before the attack Israel says rockets fired from Syria for the first time since Bashar Assad's fall - The Washington Post, with Syrian researcher Ahmed Aba Zeid noting "Until now, it's just a Telegram channel. It's not known if it is a real group" Israel says rockets fired from Syria for the first time since Bashar Assad's fall - The Washington Post. 2. Islamic Resistance Front in Syria - Awli al-Bas This is a militant faction that claims affiliation with Iran's so-called Axis of Resistance and has claimed multiple attacks against Israeli forces operating inside Syrian territory since December 2024 Syria Archives. Its logo mimics the emblem of Iran's Islamic Revolutionary Guards Corps (IRGC)—a raised arm holding an AK-47—indicating alignment with Iran-linked "resistance" groups From Al-Qaeda Commander to Syrian President: Ahmad Al-Sharaa's Ascent. Israeli Response and Syrian Accountability Israeli Defense Minister Israel Katz declared that Syria's interim president Ahmad al-Sharaa was "directly responsible for every threat and [rocket] fire toward the State of Israel" Rockets fired from Syria for first time in a year; Israel holds Sharaa responsible | The Times of Israel. Israel responded with artillery fire on the source of the rockets and carried out a series of airstrikes throughout southern Syria targeting weapons belonging to the regime Rockets fired from Syria for first time in a year; Israel holds Sharaa responsible | The Times of Israel. Analysis from Ahmad Sharawi Sharawi noted this represents "another testament to Ahmad al-Sharaa's failure to fully control all armed groups and ensure that Syrian territory will not be used as a launching point for attacks against Israel" Sharaa ‘Responsible for Every Threat': Terrorists in Syria Launch Rockets Into Israel. He emphasized that while Sharaa may not yet have full control over all armed actors, Washington should make clear that further cooperation on sanctions relief hinges on Sharaa quietly and fully cooperating with Israel to neutralize any Palestinian factions capable of launching attacks from Syrian soil Rocket Attacks on Israel Underscore Continuing Threat from Syria. The incident highlights ongoing security challenges in post-Assad Syria and the difficulty the new Syrian leadership faces in controlling various militant groups operating within its territory.

Send us a textCharles Eisenstein is a philosopher, author, and public speaker known for his deeply thoughtful explorations of civilization, consciousness, and human connection. With a background in mathematics and philosophy, Charles weaves together insights from systems thinking, spirituality, and ecology to challenge the dominant narratives of modern life. He is the author of several influential books, including The More Beautiful World Our Hearts Know Is Possible and The Ascent of Humanity, which explore how we can transition from a culture of separation to one rooted in interbeing and meaning. In a world increasingly driven by technology and abstraction, Charles offers a powerful invitation to reclaim presence, purpose, and sacredness in how we live and relate to ourselves, each other, and the Earth.Chapters00:00 The Essence of Education: Unlearning vs. Learning05:19 The Art of Self-Discovery and Unique Offerings11:30 Navigating Curiosity and Life's Path17:21 AI and the Future: Embracing Materiality32:27 The Human Experience: Beyond Abstraction39:03 The Limits of Quantification47:19 Understanding Addiction and Unmet Needs57:51 The Unquantifiable Nature of Human Experience01:06:09 The Power of Questions Over AnswersConnect with Charles! https://charleseisenstein.org/Connect with Us!https://www.instagram.com/alchemists.library/https://twitter.com/RyanJAyala

Hosted by CannCon and Zak "RedPill78" Paine, this episode of Badlands Daily unpacks the latest political theater with sharp insight and unapologetic takes. The duo dissects the so-called rift between Elon Musk and Donald Trump, weighing whether it's a real disagreement or a scripted psyop to confuse the enemy. They analyze the chaos in Los Angeles through a “trap narrative” lens, suggesting it's a strategic move by Team Trump to bait bad actors into exposing themselves. With speculation mounting around Trump's potential VP pick, possibly J.D. Vance, and a possible July announcement, the summer is shaping up to be anything but quiet. Other highlights include commentary on RICO charges in Georgia, the media's flip-flop treatment of Elon, the looming battle over Julian Assange, and Stephen Miller's legal warpath. It's a punchy, no-holds-barred episode that frames the week's events as part of a high-stakes game for control of the narrative and the future.

Preacher: Kam PughText: Psalm 121In this series titled, “Pilgrim Songs,” various preachers go through the Songs of Ascent. Pastor Kam preaches that God is our helper and keep.

In the second week of our Psalms of Ascent series, we turn our attention to Psalm 133—a brief yet powerful expression of unity among God's people. This message was delivered on Pentecost Sunday, a significant day to remember how the Holy Spirit brings us together as one body. Together, we will explore why unity is so precious to God and how it brings life, blessing, and strength to our church community.

Trace a legendary climb shrouded in mystery.

Camp Soul Dates: October 9–12, 2025 Location: A magical forest retreat in Illinois ✨ All meals, lodging, + activities included.

Air Date 6/6/2025 Today, Trump's administration is doing everything in its power to end the era of educational dominance the US has enjoyed for decades. The simple fact that explains the change is that democracy used to be valued across the political spectrum while todays Republican Party is authoritarian and understands that an educated public is a public that demands democracy while an uneducated public is much easier to manipulate and oppress. Be part of the show! Leave us a message or text at 202-999-3991 or email Jay@BestOfTheLeft.com Full Show Notes   Check out our new show, SOLVED! on YouTube! BestOfTheLeft.com/Support (Members Get Bonus Shows + No Ads!) KEY POINTS KP 1: How Trump has reshaped the federal workforce - The NPR Politics Podcast - Air Date 5-29-25 KP 2: As Trump cuts funding, researchers look for opportunities outside the U.S. - Soundside - Air Date 4-21-25 KP 3: Anti-Science Mugging on the Right and the Ascent of American Anti-Intellectualism - Citations Needed - Air Date 5-28-25 KP 4: Trump's Dark Age Admin is 'attacking the foundations of empirical knowledge', journalist says - MSNBC Reports - Air Date 5-28-25 KP 5: Trumps Rants about Harvard Get Darker as He Loses a Big One in Court - The Daily Blast - Air Date 5-29-25 KP 6: Prof Jason Stanley Trump is targeting the three pillars of democracy as he follows fascist playbook - The Dean Obeidallah Show - Air Date 6-1-25 KP 7: Worse Than McCarthyism Historian Ellen Schrecker on Trumps War Against Universities & Students - Democracy Now! - Air Date 5-30-25 KP 8: Tanya Clay House on Freedom to Learn, Danaka Katovich on Attacks on Activists - CounterSpin - Air Date 5-2-25 (01:00:04) NOTE FROM THE EDITOR  On what will fill the gap left by anti-intellectualism DEEPER DIVES (01:07:27) SECTION A: ANTI-SCIENCE (02:27:53) SECTION B: ANTI-HIGHER EDUCATION  (02:56:38) SECTION C: ANTI-PUBLIC GOODS  SHOW IMAGE CREDITS Description: An illustrated image of an arm and hand holding up a protest sign with an image of a brain on it. Credit: “brain icon mind thinking” via Mohamed_hasan, Pixabay | Pixabay license

https://slasrpodcast.com/      SLASRPodcast@gmail.com   Welcome to episode 198 of the Sounds Like a Search and Rescue Podcast, this week we are joined by Dr. Tim Warren - Tim is an accomplished mountaineer who has climbed many of the world's highest peaks including two expeditions on mount Everest where he had a success summit in 2008. We will speak with Tim about his adventures and his focus on helping others increase lifespan and healthspan centered around hiking, cross training, nutrition and headspace. Plus - more bear safety, Road openings, trailhead openings, bug gear, notable hikes, ATV crashes and recent hikes on Frankenstein Cliff / Arethusa Falls, Burnt Meadow mountain in Maine and Nick hiked the Adirondacks including Spectacled Pond, hurricane Mountain, Mount Severance and more!   This weeks Higher Summit Forecast SLASR 48 Peaks Alzheimers team - Join here!    About Our Guest About Dr. Tim Warren Topics Nick's Music Minute - Audio Slave 200 Episode Reminder - Mt. Washington Road Race  Black Bear Safety High Volume of ATV Accidents last weekend Homeless Sledgehammer attacker on Mt. Baldy Sherpa summits Mt. Everest 31st time  Reminder on Dog Safety awareness on trail  Last Breath - Movie recommendation from Stomp Recent Hikes - Frankenstein Cliff, Burnt Meadow - Adirondacks Notable Hikes  Guest of the Week - Dr. Tim Warren    Show Notes Apple Podcast link for 5 star reviews SLASR Merchandise SLASR LinkTree SLASR's BUYMEACOFFEE rock supergroup, Soundgarden, Chris Cornell, Rage Against the Machine  Out of Exile,  Note about conditions at higher elevation ATV / OTV Accidents - out of control this weekend  Man threatens hikers with a sledgehammer Kami Rita Sherpa - 31st Ascent of Mt. Everest Reminder on Dog Safety Last Breath - Movie Recommendation from Stomp SLASR 48 Peaks Alzheimers team - Join here!  Sponsors, Friends  and Partners Wild Raven Endurance Coaching 2024 Longest Day - 48 Peaks Mount Washington Higher Summits Forecast Hiking Buddies  Vaucluse - Sweat less. Explore more. – Vaucluse Gear Fieldstone Kombucha CS Instant Coffee

Friday 6/6/25

In this episode, we're joined by Taylor Morgan, a key member of the People Resources team at Ascent. With over six years of experience in human resources, Taylor brings a thoughtful and strategic approach to building more inclusive workplaces—focusing on DEI programming, employee resource groups, equitable recruiting, and professional development.  Taylor shares her journey into working with environmental professionals, her evolving perspective on the role of HR, and how organizations can reimagine hiring, internships, and culture to support equity and belonging.  This conversation offers honest insights into the work still ahead and the opportunity to transform how environmental organizations include, support, and lead with intention. 

Carolina Ascent FC are the top seed heading into the USL Super League's inaugural postseason. We're joined by two players to discuss the team chemistry, success and what needs to happen for it all to continue. We also speak with two writers to put the Ascent's season in perspective with the growing soccer culture in the Queen City.

Colorado has always been known as a distance running hotbed, and some amazing runners have come out of our high school ranks. This episode's guests are no exception – with an added twist. Bobby Kiesewetter, from Golden View Academy, a Class 2A school in Golden understandably was very concerned when his airway would shut down while he was running, making it impossible to breathe. Perplexed doctors suspected asthma and prescribed inhalers, but to no avail. Bobby happened to see a social media post from another local runner, Benji Anderson, who had experienced the same thing and had been diagnosed with Exercise-Induced Laryngeal Obstruction, also commonly called vocal cord dysfunction. Benji connected Bobby with the doctor right here in Denver who had treated him at National Jewish Hospital, which specializes in lung and breathing research. Through extensive treatment and exercises, both young men have learned to control their breathing issue and achieved great results in their high school careers. Bobby swept the Colorado Class 2A 800, 1600, and 3200 meter titles, each by wide margins, including setting a state meet record in the 1600 of 4:17.84. He will continue his running career at Division 2 Fort Lewis College in Durango, Colorado. Benji, who ran for Mountain Vista High School in Highlands Ranch, has a long list of accolades, including winning the 2024 Class 5A cross country title, is a two-time champion of the prestigious Liberty Bell Invitational, both times running the 5K course in a blazing 14:48, and has been top five in the state multiple times in the 800, 1600, and 3200. His best times include an 8:46.15 in the 3200 at Arcadia, and a 4:08.03 1600 at the New Balance indoors in Boston. He has a couple of big upcoming races before he heads off to Notre Dame this fall. Among these is the Festival of Miles this week in which a star-studded high school field will be going after sub-4:00 times. This is a great chat with a couple of very nice young men who have overcome some concerning challenges, have learned about the considerable power of the running community, and who will have many more successes in the future.Benji AndersonInstagram @benji.andersonnBobby KiesewetterInstagram @bobby_kiessBill Stahlsilly_billy@msn.comFacebook Bill StahlInstagram and Threads @stahlor and @we_are_superman_podcastYouTube We Are Superman PodcastPlease support Team Leadville and Warriors' Ascent help prevent veteran suicide! Donate here:https://give.classy.org/BillStahl2025Thank you!Subscribe to the We Are Superman Newsletter!https://mailchi.mp/dab62cfc01f8/newsletter-signupSubscribe to our Substack for my archive of articles of coaching tips developed from my more than three decades of experience, wild and funny stories from my long coaching career, the wit and wisdom of David, and highlights of some of the best WASP episodes from the past that I feel are worthwhile giving another listen.Search either We Are Superman Podcast or @billstahl8

Impulse Space has raised $300 million in a Series C funding round. Redwire's advanced lunar and Martian manufacturing technology, Mason, has passed Critical Design Review (CDR). Astroscale UK has successfully completed the Critical Design Review for the ELSA-M In-Orbit Demonstration spacecraft, and more. Remember to leave us a 5-star rating and review in your favorite podcast app. Be sure to follow T-Minus on LinkedIn and Instagram. Selected Reading Impulse Space Secures $300 Million Series C to Accelerate the Future of In-Space Mobility Redwire Receives NASA Approval to Advance Cutting-Edge Manufacturing Technology for Building Infrastructure on Moon and Mars Astroscale's ELSA-M spacecraft completes Critical Design Review Maxar and Saab Agree Strategic Partnership to Develop Multi-Domain Battlespace Solutions and Advance Europe's Space-Based Capabilities DIU selects new companies for the Hybrid Space Architecture project. (Maxar Interview) Planet Expands Business with Welsh Government for Land and Natural Resource Management Rocket Lab Schedules Third Electron Launch in 24 Days to Deploy Next Mission for iQPS Reflect Orbital Selected for SBIR Phase II Contract by AFWERX to Advance Satellite-Based Sunlight Redirection Technology IonQ Completes Acquisition of Lightsynq, Accelerating Quantum Computing and Networking Roadmap America's First Spacewalk - NASA Two space vets added to Astronaut Hall of Fame as one awaits launch- collectSPACE T-Minus Crew Survey Complete our annual audience survey before August 31. Want to hear your company in the show? You too can reach the most influential leaders and operators in the industry. Here's our media kit. Contact us at space@n2k.com to request more info. Want to join us for an interview? Please send your pitch to space-editor@n2k.com and include your name, affiliation, and topic proposal. T-Minus is a production of N2K Networks, your source for strategic workforce intelligence. © N2K Networks, Inc. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Psalms of Ascent remind us that faith moves upward even when life feels like it's falling apart. Jesus' journey from Palm Sunday to Gethsemane shows us the reality of both joy and sorrow on the road of obedience. Pastor Mark Kelsey highlights that our direction matters more than our condition. Jesus stayed oriented toward the Father, anchored in identity, not emotion. His surrender “Not my will, but yours be done” wasn't weakness, but strength. We're invited into the same posture. In every season, God is present. Nothing can separate us from His love. 

It's a special day at Ascent as we begin our new series "Summer Setlist."  We are celebrating baptisms! Listen as Pastor T brings an encouraging message entitled, "Never Forget Who You Are."Connect with our church: @ascentchurchva Connect with our lead pastor: @pastor.tlane

Big ideas, bold flavors, and unfiltered insights—welcome to Austin, where the future of CPG is being written in real time. At Taste Radio's Austin Meetup, we sat down with trailblazers and trendsetters redefining how brands are built and scaled. From Better Sour co-founder Bella Hughes to Torchy's Tacos founder Mike Rypka and Snaxshot's Andrea Hernández, these conversations explore what it really takes to innovate, connect with consumers, and lead with authenticity in a rapidly evolving industry. Show notes: 0:45: Buyers As Far As The Eye Can See. NNE FTW. Boiler Room. Caffeine, Protein & Pole-Caught Tuna. With BevNET Live just two weeks away, excitement is building as Casey's joins a strong lineup of participating retailers, including Stop & Shop, Whole Foods Market, Circle K, H-E-B, The Goods Mart, and Top Ten Liquors. John and Ray recap the recent Naturally New England Naturally Rising event, which spotlighted standout emerging brands, including Singing Pastures and Farmer Foodie. Mike and John revisit their tour of Athletic Brewing's HQ in Milford, CT, before the hosts riffed on consumer interest in dual-functionality products and a canned tuna brand grounded in sourcing transparency. 19:23: Interviews from Taste Radio's Austin Meetup – Mike Rypka, the visionary founder of Torchy's Tacos, shared his journey from launching a food trailer to building a nationally recognized franchise. Steven Santangelo of Matriarch Wealth Management discussed how his firm helps CPG founders navigate the complexities of financial planning, particularly during critical growth and exit stages. Bella Hughes, co-founder of Better Sour, reflected on building a culturally inspired candy brand and the challenges of innovation in a legacy category. Andrea Hernández, the sharp mind behind Snaxshot, delivered an unfiltered perspective on food and beverage trends, highlighting the importance of authenticity and emotional resonance in brand storytelling. And Michelle Breyer, CMO of the Texas-based accelerator SKU, shed light on how the organization nurtures early-stage consumer brands, emphasizing the pivotal role of founder mindset and market fit in driving long-term success. Brands in this episode: Better Sour, Torchy's Tacos, Farmer Foodie, Monsoon Kitchens, Inc., Granny Squibb's, TITIN, Fancypants Baking Co., Singing Pastures, Athletic Brewing, Lucky Saint, 5-hour Energy, Ascent, Pole & Line, Fly By Jing, Siete, Wildwonder, Bachan's, Daily Crunch, Leisure Hydration, BodyArmor, Vitaminwater, NoBull

In this episode we detail demagogues' favorite faux populist schtick of taking scientific studies out of context and mocking them, often with help from mainstream media. with guest Brenda Ekwurzel, director of climate science for the Union of Concerned Scientists.